Voyager Therapeutics
VYGR
78 hedge funds and large institutions have $96.8M invested in Voyager Therapeutics in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 28 reducing their positions, and 39 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less call options, than puts
Call options by funds: $718K | Put options by funds: $747K
9.55% less ownership
Funds ownership: 71.68% → 62.14% (-9.5%)
23% less funds holding
Funds holding: 101 → 78 (-23)
25% less capital invested
Capital invested by funds: $130M → $96.8M (-$33M)
29% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 28
59% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$6.18M |
| 2 |
Millennium Management
New York
|
+$2.35M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$1.83M |
| 4 |
Morgan Stanley
New York
|
+$1.23M |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$816K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$7.16M |
| 2 |
ClearBridge Investments
New York
|
-$6.52M |
| 3 |
WHCM
Wolf Hill Capital Management
Greenwich,
Connecticut
|
-$4.16M |
| 4 |
JP Morgan Chase
New York
|
-$1.94M |
| 5 |
State Street
Boston,
Massachusetts
|
-$1.84M |
VYGR Hedge Fund Activity: Q2 2021 in Review
78 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q2 2021, worth a combined $96.8M — down 25% from $130M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of VYGR and 16 opened new positions — a net loss of 23 holders — while 28 trimmed existing stakes and 20 added.
The largest buyer was Citadel Advisors, adding an estimated $6.18M. The largest seller was BlackRock, cutting an estimated $7.16M.
- 78 institutional investors held Voyager Therapeutics (VYGR) as of Q2 2021, down from 101 in Q1 2021.
- Funds reported $96.8M of Voyager Therapeutics stock for Q2 2021, down 25% quarter-over-quarter.
- 16 funds opened new Voyager Therapeutics positions in Q2 2021 and 39 closed out, a net change of -23 holders.
- The largest Voyager Therapeutics buyer in Q2 2021 was Citadel Advisors, an estimated $6.18M added.
- The largest Voyager Therapeutics seller in Q2 2021 was BlackRock, an estimated $7.16M sold.
Based on aggregated 13F filings for Q2 2021.